These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25057302)

  • 21. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
    Baselga J
    Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.
    Ogita S; Lorusso P
    Target Oncol; 2011 Jun; 6(2):103-17. PubMed ID: 21547565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K/Akt/mTOR inhibitors in breast cancer.
    Lee JJ; Loh K; Yap YS
    Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.
    Zhang X; Li XR; Zhang J
    Curr Cancer Drug Targets; 2013 Feb; 13(2):175-87. PubMed ID: 23215724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
    Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
    Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
    Zhao M; Ramaswamy B
    World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
    Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
    Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.
    Yang XL; Lin FJ; Guo YJ; Shao ZM; Ou ZL
    Onco Targets Ther; 2014; 7():1033-42. PubMed ID: 24966685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.
    Vitale SR; Martorana F; Stella S; Motta G; Inzerilli N; Massimino M; Tirrò E; Manzella L; Vigneri P
    Crit Rev Oncol Hematol; 2021 Jun; 162():103334. PubMed ID: 33865994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.
    Hasson SP; Rubinek T; Ryvo L; Wolf I
    Breast Care (Basel); 2013 Aug; 8(4):248-55. PubMed ID: 24415977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.
    Xia Q; Xu M; Zhang P; Liu L; Meng X; Dong L
    Front Oncol; 2020; 10():572904. PubMed ID: 33123479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
    Janku F
    Cancer Treat Rev; 2017 Sep; 59():93-101. PubMed ID: 28779636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
    Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
    Wilks ST
    Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.